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Summary
Microarray technologies are powerful tools which allow us to quickly observe the
changes at the differential expression levels of the entire complement of the genome
(cDNA) under different induced conditions. Under these different conditions, it is
believed that important information and clues to their biological functions can be
found.
In the past decade, numerous microarray experiments were performed. How-
ever, due to the large amount of data, it is difficult to analyze the data manually.
Recognizing this problem, some researchers have applied machine learning tech-
niques to help them understand the data (Alizadeh et al., 2000; Alon et al., 1999;
Brown et al., 2000; Golub et al., 1999; Hvidsten et al., 2001). Most of them tried
to do classification on these data, in order to differentiate two different possible
classes, e.g tumor and non-tumor or two different types of tumors. Generally, the
main characteristic of the microarray data is that it has large number of genes but
rather small number of examples. This means that it is possible to have a lot of
redundant and irrelevant genes in the dataset. Thus, it is useful to apply feature
selection tools to select a set of useful genes, before feeding into a machine learn-
ing techniques. These two areas, i.e. gene microarray classification and feature
selection, are the main tasks for this thesis.
We have applied Gaussian Processes with Monte Carlo Markov Chain (MCMC)
treatment as classification tool, and Automated Relevance Determination (ARD)
in Gaussian Processes as feature selection tool for the microarray data. Gaussian
Processes with MCMC treatment is based on a Bayesian probabilistic framework
to make prediction (Neal, 1997). It is a very powerful classifier and best suited for
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problem with a small number of examples. However, the application of Bayesian
modelling scheme into the interpretation of Microarray dataset is yet to be inves-
tigated.
In this thesis, we have used this machine learning to study the application of
Gaussian Processes with MCMC treatment in four datasets, namely Breast cancer
dataset, Colon cancer dataset, Leukaemia dataset and Ovarian cancer dataset.
It will be expensive to directly apply Gaussian Processes on the datasets. Thus,
filter methods, namely Fisher Score and Information Gain, are used for the first
level of feature selection process. Comparisons are done upon these two methods.
We have found out that these two filter methods, generally, gave comparable
results.
To estimate the quality of the selected feature, we use the technique of ex-
ternal cross-validation (Ambroise and McLachlan, 2002), which gives an unbiased
average test accuracy. In this technique, the training data is split into different
folds. The gene selection procedure is executed, each time using training dataset
that excludes one fold. Testing will be done on the fold omitted. From this av-
erage test accuracy, the combination of filter methods and ARD feature selection
methods gives results that are comparable to those in the literature (Shevade and
Keerthi, 2002). Though it is expected that average test accuracy is higher than
validation test accuracy, the average test accuracy obtained is also considerably
good, particularly in Breast Cancer dataset and Colon Cancer Dataset.
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In the recent years, biological data are being produced at a phenomenal rate.
On average, the amount of data found in databases such as GenBank double in
less than 2 years time (Luscombe et al., 2001). Besides, there are also many
other projects, closely related to the gene expression studies and protein structure
studies, that are adding numerous amount of information to the field. This surge in
data has heightened the need to process them. As a result, computers have become
an indispensable element to biological research. Since the advent of information
age, computers are used to handle large quantities of data and investigate complex
relations, which may be observed in the data. The combination of these two fields
has given rise to a new field, Bioinformatics.
The pace of data collection has been once again speeded up with the arrival of
DNA microarray technologies (Genetics, 1999). It is one of the new breakthroughs
in experimental molecular biology. With thousands of gene expression processed
in parallel, microarray techniques are producing huge amount of valuable data
rapidly. The raw microarray data are images, which are then transformed to
gene expression matrices or tables. These matrices have to be evaluated if further
knowledge concerning the underlying biological process is to be extracted out. As
the data is huge, studying the microarray data manually is not possible. Thus, to
evaluate and classify the microarray data, different methods in machine learning
are used, both supervised and unsupervised methods (Bronzma and Vilo, 2001).
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In this thesis, the focus will be on a supervised method, i.e. the outputs of the
training examples are known and the purpose is to predict the output of new
example. In most of the cases, the outputs are either of two classes. Hence, the
task is to classify a particular example of the microarray data, predicting it to
be tumor or non-tumor (Colon Cancer dataset), or differentiating it between two
different cancer types (Leukaemia dataset).
In most cases, the number of examples in a typical microarray data set is
small. This is so because the cost of applying and evaluating different conditions
and evaluating on the samples is relatively high. Yet, the data is very large due
to the huge number of genes involved, ranging from a few thousands to hundreds
of thousands. Thus, it is expected that most of the genes are irrelevant or redun-
dant. Generally, these irrelevant and redundant features would not be helpful in
the prediction process. In fact, there are many cases in which irrelevant and redun-
dant features decrease the performance of the machine learning algorithm. Thus,
feature selection tools are needed. It is hoped that by applying feature selection
methods on microarray datasets, we are able to eliminate a substantial number of
irrelevant and redundant features. This will improve the machine learning process
as well as reduce the computational effort required. This is the motivation of the
thesis.
1.1 Literature Review
There are several papers working on these two areas, i.e., gene microarray classifi-
cation and feature selection in gene microarray datasets. Furey et al. (2000) have
employed Support Vector Machines to classify three datasets, which are Colon
Cancer, Leukaemia and Ovarian datasets. Brown et al. (2000) also applied Sup-
port Vector Machines in gene Microarray datasets. Even though the number of
examples available is low, the authors are still able to obtain low testing errors.
Thus, the method is popular. Besides Support Vector Machines, Li et al. (2001a)
have combined a Genetic Algorithm and the k-Nearest Neighbor method to dis-
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criminate between different classes of samples, while Bendor et al. (2000) used a
Nearest Neighbor method with Pearson Correlation. Nguyen and Rocke (2002)
used Logistic Discrimination and Quadratic Discriminant Analysis for predicting
human tumor samples. Naive Bayes method (Keller et al., 2000) is also employed.
Also, Dudoit and Speed (2000) employed a few methods, namely, Nearest Neigh-
bor, Linear Discriminant Analysis, Classification tree with Boosting, and Bag-
ging for gene expression classification. Meanwhile, Shevade and Keerthi (2002)
have proposed a new and efficient algorithm based on Gauss-Seidel method to
address gene expression classification problem. Recently, Long and Vega (2003)
used Boosting methods to obtain cross validation estimates for the Microarray
datasets.
For gene selection, Furey et al. (2000), Golub et al. (1999), Chow et al. (2001)
and Slonim et al. (2000) made used of Fisher Score as the gene selection tool.
Weston et al. (2000) also used information in kernel space of Support Vector
Machines as a feature selection tool to compare with Fisher Score. Guyon et al.
(2002) have introduced Recursive Feature Elimination based on Support Vector
Machines to select relevant genes in gene expression data. Besides, Li et al. (2001b)
has used Automated Relevance Determination (ARD) of Bayesian techniques to
select relevant genes. Ben-Dor et al. (2000) have examined Mutual Information
Score, as well as Threshold Number of Misclassification to find relevant features
in gene microarray data.
In this thesis, we will investigate the usefulness of Gaussian Processes with
Monte Carlo Markov Chain (MCMC) treatment, as the classifier for the microar-
ray datasets. Gaussian Processes is an attractive method for several reasons. It
is based on the Bayesian formulation and such a formulation is known to have
good generalization property in many implementations. Instead of making point
estimates (Li et al., 2001b), the method makes use of MCMC to sample on the
evidence distribution. Besides this probabilistic treatment, it is also a well known
fact that the method performs well with small number of examples and many fea-
tures. We will also make use of the Automated Relevance Determination (ARD)
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that is inherent in Gaussian Processes as the feature selection tool. We will discuss
Gaussian Processes, MCMC and ARD in detail in Chapter 3.
As mentioned, we have used the probabilistic framework of Gaussian Processes,
with the external cross validation methodology to predict as well as select relevant
features. Based on the design, we can observe encouraging results. Except for the
Leukaemia dataset, the results of the other three datasets show that the method-
ology perform competitively, compared with the results of Shevade and Keerthi
(2002). However. we would like to emphasize that it is not the aim of this project
to solve the problem and come out with a set of genes which we will claim as the
cause of cancers. But, we would like to highlight a small number of genes which
the Gaussian Processes methodology, have identified as the relevant genes in the
data. We hope that this method can be a tool to help the biologists shorten their
time to find out the genes responsible of certain disease. With the knowledge gain,
they may apply necessary procedures or drugs to prevent the disease.
1.2 Organization of Thesis
The thesis is arranged in the following way. Chapter 2 describes feature selections
methods for two classes problem, which are used in the thesis. An introduction
of Gaussian Processes is given in Chapter 3. Gaussian Processes is a learning
model for regression and classification tasks with a Bayesian framework. This
framework is described in detail. Also, MCMC and ARD will be discussed in
Chapter 3 as well. In Chapter 4, DNA microarray technology will be briefly
mentioned, together with a short description of the four microarray datasets used
throughout the thesis. Then, Chapter 5 describes some experiments to gain a
better understanding on the Gaussian Processes. Chapter 6 concentrates on the
methodology of the experiments. Then, the results and discussions based on the





The microarray data are known to be of very high dimension (corresponding to
the number of genes) and having few examples. Typically, the dimension is in the
range of thousands or tens of thousands while the number of examples lies in the
range of tens. Many of these features are redundant and irrelevant. Thus, it is
a natural tactic to select a subset of features (i.e. the genes in this case) using
feature selection.
Generally, feature selection is an essential step that removes irrelevant and
redundant data. Feature selection methods can be categorized into two common
approaches: the wrapper method and the filter method (Kohavi and John, 1996;
Mark, 1999).
Wrapper method includes the machine-learning algorithm in evaluating the
importance of features in predicting the outcome. This method is supported with
the thought that bias of a particular induction algorithm should be taken into
account when selecting features. A general wrapper architecture is described in
Figure 2.1.
Wrapper method conducts a search on the number of input features. The
techniques used can be forward selection (a search begins with the empty set of
features and add in feature or a set of features with certain criteria), backward
elimination (a search begins with the full set of features) or best first search (a
search that allows backtracking along search path). Wrapper method will also
5
Figure 2.1: Architecture of wrapper method.
Figure 2.2: Architecture of filter method.
require feature evaluation function together with the learning algorithm to esti-
mate the final accuracy of feature selection. The function can be a re-sampling
technique such as k-fold cross validation or leave-one-out cross validation. Since
wrapper method is tuned to interactions between an induction algorithm and its
training data, it generally gives better results than filter method. However, to
provide such an interaction, the learning algorithm is repeatedly called. This, in
practice, may be too slow and computationally expensive for large datasets.
As for filter method, a heuristic is used, which is based on the characteristics
of the data, to evaluate the usefulness of the features before evaluation with the
learning algorithm. Independently on the learning algorithm, filter method is
generally much faster than wrapper method. Thus, it is suitable for data of high
dimensionality and many features. A general filter architecture is shown in Figure
2.2.
For most of the cases, filter method fails to recognize the correlation among
the features. Filter method also requires the user to set a level of acceptance on
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choosing the features to be selected, which requires experience of the user.
In this project, before applying Automated Relevance Determination (ARD),
we use filter methods to reduce the number of features. This is mainly to avoid
the huge dimension of the raw data to be fed into Gaussian Processes. The filter
method that is being used here is Fisher Score and Information Gain. These two
filter methods are widely used in Pattern Recognition for two-class problems. We
will discuss these two filter methods in the next two sections.
2.1 Fisher Score
Fisher Score is an estimate of how informative a given data is, based on means and
variances of two classes of the data. The method is only suitable for continuous







where µi and σi are the mean and standard deviation of data from class i.
The numerator of (2.1) is a measure of the distance between the two means of
classes. Intuitively, if the two means are far apart, it is easier for the data to be
recognized as two classes. Thus, if the numerator value is high, it means that the
data is informative to differentiate the class.
However, just using the means are not sufficient. For example, a feature is
not a strong feature if its means of the two classes are very much different and,
at the same time, the variances of the two classes are also huge (i.e. the data of
each class are widely spread). The situation will be even worse if the variance is
so huge that there is much overlap region of the data. Thus, the denominator of
(2.1) is introduced to overcome this situation.
Thus, Fisher Score is a measurement of the data in term of its distribution.
The value of the score is high if the two means of the classes are very different and
the data of each class are crowded near the mean of the data.
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Fisher Score has been widely used in the microarrays data as the filter method
for the reduction in the number of features (Golub et al., 1999; Weston et al., 2000;
Furey et al., 2000; Chow et al., 2001; Slonim et al., 2000). Though the expression
may differ from (2.1), the essential meaning is pretty similar. A summary of the
expressions of Fisher Score used in the literature are given below:












In the thesis, we will use (2.1).
2.2 Information Gain
Information gain is a filter method that is based on entropy (information the-
ory). Entropy is a measurement of uncertainty in a system. The entropy of a





where p(x) is the probability for x to happen.
However, entropy can also be used as a measure of independency. For this
purpose, let x be the feature and t be the class. To check the entropy of a joint
event when a feature occurs together with the class, the joint entropy is given as





p(x, t)log2(p(x, t)) (2.6)
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where p(x, t) is the joint probability for (x, t) to occur.
Equations (2.5) and (2.6) are used for computing the information gain of a










Equation (2.7) is simply a measure of the reduction in uncertainty about a
variable (for example, the feature in this case) due to the knowledge of another
variable (the class in this case )(Duda et al., 2001). Thus, it is actually a measure
of how much the distributions of the variables (the class and a feature) differ from
statistical independency of these two variables.
The value of information gain is always greater than zero. From (2.7), it can
be observed that if the class and the feature are independent, the value of mutual
information is equal to zero. Hence, the greater the values of information gain,
the higher the correlation between a feature and the class.
However, in most cases, the distributions of variables are not known. In order
to use information gain, there is a need to discretize the gene expression values.
In this project, we employed the Threshold Number of Misclassification (TNoM)
method suggested by Ben-Dor et al. (2000) as the discretization method. It is
based on the simple rule that uses the value, x,of expression level of a gene. The
prediction class, t, is simply sign(ax + b), where a²(−1,+1). A straightforward





1{ti 6= sign(axi + b)} (2.8)
which means if the prediction and the label of an example are different, error is
increased by one.
In this case, instead of using the (a, b) which give minimum errors of misclas-
sification, the (a, b) that give the maximum value of information gain over the
various possible discretizations is used. Once (a∗, b∗) are found after 2(n + 1)
possible search (where n is the number of possible values of x), information gain
9
(2.7) can be found too. In short, TNoM (2.8) is used as a binning method before
Equation (2.7) is applied.
2.3 Automatic Relevance Determination





This chapter presents a review on Gaussian Processes. It is first inspired by Neal’s
work (Neal, 1996) on priors for infinite networks. In spirit, Gaussian Processes
models are equivalent to a Bayesian treatment of a certain class of multi-layer
perceptron networks in the limit of infinitely large networks (i.e. with an infinite
number of hidden nodes). This is shown experimentally by Neal (Neal, 1996). In
Bayesian approach to neural networks, a prior on the weights in the network in-
duces a prior distribution over functions. When the network becomes very large,
the network weights are not represented explicitly. The priors of these weights
are represented a simpler function in Gaussian Processes treatment. The math-
ematical development of this can be found in Williams (1997). Thus, Gaussian
Processes achieves an efficient computation of prediction based on a stochastic
process priors over functions.
The idea of having prior distribution over the infinite-dimensional space of
possible functions have been known for many years. O’Hagan (O’Hagan, 1978)
has used Gaussian priors over functions for his development. Generalized radial
basis functions (Poggio and Girosi, 1989), ARMA models (Wahba, 1990) and
variable metric kernel methods (Lowe, 1995) are all closely related to Gaussian
Processes. The same model has long been used in spatial statistics known as
“kriging” (Journel and Huijbregts, 1978; Cressie, 1991).
The work by Neal (Neal, 1996) has motivated examination of Gaussian Pro-
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cesses for the high dimensional applications to which neural networks are typically
applied, both on regression and classification problems (Williams and Rasmussen,
1996; Williams and Barber, 1998; Gibbs, 1997).
One of the common DNA microarray problems is the classification problem
based on gene expressions (i.e. differential expression levels of the gene under
different induced conditions). The task is to use the gene expression levels to
classify groups to which an example belongs. There are a few classification meth-
ods that use Gaussian Processes: Laplace approximation (Williams and Barber,
1998), Monte Carlo method (Neal, 1997), variational techniques (Gibbs, 1997;
Seeger, 1999) and mean field approximations (Opper and Winther, 1999). For
this thesis, we will mainly focus on Neal’s work which uses the technique of Monte
Carlo Markov Chain (MCMC). Thus, in the following sections of this chapter, we
will discuss the classification model based on MCMC Gaussian Processes.
3.1 Gaussian Processes Model for Classification
We now provide a review of the Gaussian Processes methodology and the associ-
ated nomenclature. See Neal (1996) for detailed discussion of this method.
We will use the following notations. x with d dimension is a training example.
n is the total number of training examples. Let {x}n denotes the n example of
inputs, x. The true label is denoted as t˜. T denotes n numbers of training data,
both inputs ({x}n) and outputs (true labels). The Gaussian Processes for classi-
fication is based on the regression methodology. In the regression methodology,
the predicting function of the regression is y(x), which is also known as latent
function. Y = {y(x1), y(x2), . . . , y(xn)} denotes n numbers of latent functions. cij
is the covariance function of input xi and xj. C is the covariance function matrix
with elements cij. Let us denote the prediction of the input as t(x), which only
take two values (i.e. +1 or 0). x∗ denotes the testing input. Accordingly, t(x∗) is
the predicting label of testing input.
Gaussian Processes is based on Baye’s rule, for which a set of probabilistic
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models of the data is specified. These models are used to make predictions. Let’s
denote an element of the set (or one model) by H, with a prior probability, P (H).
When the data, T , is observed, the likelihood of H is P (T |H). By Baye’s rule,
the posterior probability of H is then given by
posterior ∝ prior × likelihood (3.1)
P (H|T ) ∝ P (H)× P (T |H) (3.2)
The main idea of Gaussian Processes is to predict the output y(x) for a given
x. Each model, H, is related to y(x) by P (y(x)|H). Hence, if we have a set of
probabilistic models, a combined prediction of the output y(x) is
P (y(x)|T ) =
∑
allH
P (y(x)|H)× P (H|T ) (3.3)
In the above, y(x) is typically a regression output, i.e., y(x) is a continuous
output. This output is also known as latent function. For a classification problem,
the above has to be expanded.
In a typical two-class classification problem, we assign a testing input, x∗, to
class 1 if
P (t(x∗) = +1|T ) (3.4)
is greater than 0.5 and class 2 (i.e. true label is 0) otherwise.
We can find (3.4) by using a sigmoidal function over the latent function y(x∗),
through a transfer function, in the following manner
P (t(x∗) = +1|T )
=
∫
P (t(x∗) = +1|y(x∗))P (y(x∗)|T ) dy(x∗) (3.5)
where
P (t(x∗) = +1|y(x∗)) (3.6)
13
is a sigmoidal function given by
(1 + exp(−y(x∗))−1 (3.7)
From (3.5), to make prediction of the two-class classification problem, we need
to find the probability distribution of a predictive function, y(x∗), given all the
training data, T , i.e.
P (y(x∗)|T ) (3.8)
In order to find (3.8), let us assume a Gaussian model as the prior of the latent
functions, Y, i.e.,






Y tC−1Y ) (3.9)
Meanwhile, the joint prior probability of {Y, y(x∗)} is given by









where C+ is the covariance function matrix of {{x}n, x∗}, and Y+ is the vector
{y(x∗), Y }. Generally, a covariance function is parameterized by a few parameters.
These parameters are known as hyper-parameters, denoted by Θ.
Based on (3.9) and (3.10), the conditional probability P (y(x∗)|Y,Θ) is normally
distributed with mean ktC−1Y and variance k∗−ktC−1k, where k∗ is the covariance
function of x∗, while k is the covariance function vector of all inputs and x∗.
With that, P (y(x∗)|T,Θ) can be written as
P (y(x∗)|T,Θ) =
∫
P (y(x∗)|Y,Θ)P (Y,Θ|T )dY (3.11)
Thus if the distribution of Θ is known (3.11) can be re-expressed as
P (y(x∗)|T ) =
∫ ∫
P (y(x∗)|Y,Θ)P (Y,Θ|T )dY dΘ (3.12)
The MCMC sampling process will give us iterative values for Y and Θ. Thus,
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through these samplings, (3.12) can be re-expressed as





where R is the number of sampling iterations, while Yi and Θi are the values of
latent functions and hyper-parameters of ith iteration.





P (t(x∗) = +1|y∗(x∗))P (y(x∗)|Yi,Θi) (3.14)
(3.14) will give the posterior probability of a testing input, x∗, to be class 1. We
will use this posterior probability to make prediction in the two class classification.
From above, to obtain the possible values, a full MCMC treatment is applied
over P (Y,Θ|T ), which can be done over a two stage process, first by fixing Θ
and finding P (Y,Θ|T ) through sampling and followed by fixing Y and finding
P (Y,Θ|T ).
We will discuss the theory of MCMC in a more detail manner in Section 3.3 .
Let us discuss how we apply MCMC first.
For fixed Θ, each of the n individual functions, y(x), are updated sequently
using Gibbs sampling, which we will discuss more about Gibbs sampling in section
3.3.1. The Gibbs sampling is done for a few scans as it takes a much shorter
time to do such sampling. Also, the conditional probability is readily found.
After employing Gibbs sampling, candidates of latent functions, let’s say Yi,can
be obtained.
Secondly, for fixed Y , the hyper-parameters are updated using the Hybrid
Monte Carlo method (HMC). We will discuss HMC in more details in Section
3.3.2.
This full Bayesian treatment with MCMC approach of defining a prior over
the functions as well as parameters is a powerful approach. One need not be
concerned about inaccuracy due to point estimation. Bayesian treatment will
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consider as much location as possible, (theoretically, all locations) in the function
space. Also, MCMC random walking (sampling) in the hyper-parameter space
will be able to overcome the problem faced due to integration in the formulation
(we will discuss this point in Section 3.3). Applying MCMC will be able to search
the function as well as hyper-parameter spaces numerically. Most importantly, the
two MCMC methods that are employed, i.e. Gibbs Sampling and HMC, are able
to work under high dimensional function and hyper-parameter space respectively,
unlike other sampling such as important sampling, which become difficult if the
dimensions are too high.
3.2 Automatic Relevance Determination
In equations (3.13) and (3.14) we have grouped all parameters of the covariance
function as Θ. It is possible to include feature selection ability through this pa-
rameterization. Suppose the covariance function is chosen as linear covariance











where σl and σc are the Θ.
From (3.15), σl and σc, where l is from 1 to d (which are corresponding to 1 to
d features), are the vectors required to parameterize covariance function. When
the expected value of the σl is small, the model will ignore the input dimension.
This implies that the feature corresponding to the σl is irrelevant. For relevant
input dimension, corresponding σl will be big in value. In this case, the model will
be hugely depending on the input dimension.
Since this type of build-in relation is found in Gaussian Processes in an “au-
tomated” form, and also, it is a measurement of relevance of feature, it is called
as Automatic Relevance Determination (ARD)(Mackay, 1993; Neal, 1996).





P (Θ|T )ΘdΘ (3.16)
which we can find by using
E(Θ|T ) =
∫ ∫
P (Y,Θ|T )ΘdΘdY (3.17)
The process for obtaining (3.14) is actually obtaining (3.17) at the same time.
By employing MCMC to sample on P (Y,Θ|T ), the equation (3.17) becomes





This shows that the ARD values , i.e. Θ, which obtained based on MCMC
method, is statistically meaningful. The two stage process is able to obtain the
statistical expected value of these hyper-parameters.
3.3 Monte Carlo Markov Chain
Let us discuss Monte Carlo Markov Chain (MCMC) now as both the predictions
of Gaussian Processes for Classification, (3.12) and ARD, (3.18) require the use of
MCMC. We will only discuss it briefly. For details of MCMC, the theorems and
proofs can be found in (Gilks et al., 1996; Neal, 1993; Tanner, 1996).
The two main uses of Monte Carlo, as a sampling method, are to generate
samples from a given distribution P (x) or to estimate expectation of a function
under a given distribution P (x) (Mackay, 1998). Suppose that we have a set of
random variables θ1, θ2, ..., θn, which may describe the characteristic of a model,
taking the values as q1, q2, ..., qn, the expectation of a function, f(θ1, θ2, ..., θn) with







f(q1, q2, ...qn)P (θ1 = q1, θ2 = q2, ..., θn = qn) (3.19)
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where i is the i-th point (sampling) in the sample. The sampling approach is what
has been applied in Section 3.1 (equation (3.14)) and 3.2 (equation (3.18)) .
As for Markov chain, it is specified by an initial probability distribution, P 0(Θ)
and a transition probability T (Θ′; Θ). The probability distribution of the param-
eter at i-th iteration of Markov chain can be expressed as
P i+1(Θ′) =
∫
T (Θ′; Θ)P i(Θ)dΘ (3.21)
Note that Markov Chain is an iteration sampling process, as shown in (3.21).
The iteration effect will be clearly seen when we evaluate posterior probability
(3.14) and expected value of hyper-parameters (3.18), when we discuss some im-
plementation issues in Chapter 5.
During the construction of the chain, two things have to be assured. Firstly, the
desired distribution has to be the invariant distribution of the chain. A distribution
pi(Θ) is invariant if it satisfies the following relation
pi(Θ′) =
∫
T (Θ′; Θ)pi(Θ)dΘ (3.22)




P i(Θ) = pi(Θ) (3.23)
Normally, it is more convenient and easier to construct transition probabilities
which satisfy the detailed balance condition
T (Θ′; Θ)pi(Θ) = T (Θ;Θ′)pi(Θ′) ∀Θ andΘ′ (3.24)
18
If (3.24) holds, then it is sufficient to prove that a Markov chain simulation
will converge to the desired distribution.
To generate points drawn from the distribution with reasonable efficiency, the
sampling method must search for relevant regions, without bias. The combination
of Markov chain and Monte Carlo, i.e. MCMC, has the ability to search a dis-
tribution where parameter of the framework will come to a correct distribution,
(provided that the probability distribution satisfies Equation (3.24)), and being
generated in the limit as the length of chain grows, a fundamental of Markov chain
as explained above (Equation (3.23)). Nevertheless, it is not practical to generate
an infinite length of iterations. We need to find out a suitable way to identify the
on-set of the equilibrium state where the invariant distribution is reached. We will
discuss this in Chapter 5.
Two methods in MCMC are used in this thesis, which are Gibbs sampling and
Hybrid Monte Carlo. We will discuss these two sampling methods in the following
sections.
3.3.1 Gibbs Sampling
Neal has employed Gibbs Sampling to find the candidates of function, y(x). This
sampling uses a conditional distribution to find the next candidate. Thus, if
the distribution, from which samples are needed to be solved, having conditional
distributions that can be easily formulated, or the values of the parameters can
be easily sampled from, Gibbs sampling is prefered.
In Gaussian Processes, the conditional probability of the problem is to sample
the function from the Gaussian conditional distribution. The conditional distri-
bution for y(x) given the other functions, is
p(y(xi)|y(xn−i)) ∝ exp(−1
2
Y tC−1Y ) (3.25)
where y(xn−i) denotes all the functions exclusive of function y(xi).
With (3.25), the selection of the next candidate is quite straight forward. In
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a case of a problem where there are n functions, a single scan involves sampling
one function at a time:
y(x1)
t+1 ∼ p(y(x1)|y(x2)t, y(x3)t, . . . , y(xn)t) (3.26)
y(x2)
t+1 ∼ p(y(x2)|y(x1)t+1, y(x3)t, . . . , y(xn)t) (3.27)
...
y(xn)
t+1 ∼ p(y(xn)|y(x2)t+1, y(x3)t+1, . . . , y(xn−1)t+1) (3.28)
It can be proven that a single scan with conditional probability is a transitional
probability that satisfies detailed balance (3.24) (Neal, 1993).
By sampling based on (3.26) to (3.28), candidates of Yi can be obtained.
3.3.2 Hybrid Monte Carlo
The Hybrid Monte Carlo (HMC) method is a MCMC method that reduces random
walk behavior (Duan et al., 1987) by making use of the gradient information of
the particular distribution. In Gaussian Processes, the gradient of the evidence
for hyper-parameter (Θ) can be found as shown in (3.41). Thus, if the gradient
of the distribution being investigated is available, HMC can be employed to speed
up searching of the hyper-parameter space.





where E(Θ) is the potential energy, Θ in this case is the displacements and Z is
the normalization factor.
In HMC, an independent extra set of momentum variables, p = p1, p2, . . . , pd+2,
with independent and identically distributed (i.i.d.) standard Gaussian distribu-
tion is introduced. With the momentum variables, we can add a kinetic term
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K(p) to the potential term E(Θ) to produce a full Hamiltonian energy function
on a phase-space
H(Θ,p) = E(Θ) +K(p) (3.30)







Using linear covariance function (3.15), the number of p is d + 1, where there
are d of σls as well as the αc.
The invariant distribution in MCMC for this Hamiltonian is, thus,
pi(Θ,p) ∝ exp(−H(Θ,p)) (3.32)
The proof that (3.32) is an invariant distribution can be found in (Neal, 1993).
The reason to introduce an extra set of kinetics term, though is burdensome due
to enlarging dimensions, is to find a candidate that is far away from the current
state by following the dynamics path in phase-space.
Another important ingredient for HMC is the step of leapfrog discretization,
employed to simulate the Hamiltonian dynamics. Leapfrog discretization updates
θi and pi in three steps.















where ² is the time step of a leapfrog discretization.


























With the leapfrog, we will be able to find a set of hyper-parameters candidates.
The candidate will be accepted based on the probability of acceptance
min{1, exp[−H(Θ(t+²),p(t+²)) −H(Θ(t),p(t))]} (3.36)
In summary, the HMC algorithm operates as follows:
1. Randomly choose a direction, λ (either +1 or −1).
2. Starting the state, (Θ0,p0), perform L leapfrog steps with step size λ², re-
sulting in the state (Θ∗,p∗)
3. Based on (3.36), decide the new state (Θ0,p0) or (Θ∗,p∗)
There are a few variations of HMC (Horowitz, 1991; Neal, 1994). However, the
main ideas are similar to the one described above. The difference is that those
methods are to further speed up the process of searching in the phase-state.
From above, in order to employ HMC, we need to obtain the gradient of
P (Y,Θ|T ) with respect to Θ.
Let
Ψ(Y,Θ) = lg (P (Y,Θ|T )) (3.37)
Since P (T |Y,Θ) = P (T |Y ) as T is independent of Θ given Y . This gives
Ψ(Y,Θ) = lg
(P (T |Y )P (Y |Θ)P (Θ))
P (T )
(3.38)
By substituting (3.7), and (3.10) with some manipulations, we will get









lg 2pi+lgP (Θ)−lgP (T )
(3.39)
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Now, reasoned by (Neal, 1996), we can assume a Gamma model as the prior
of the hyper-parameters, which is
P (Θ) ∝ Θ(a−1)e(−b∗Θ) (3.40)
where a and b are two parameters to be tuned. We will discuss these two param-
eters in Chapter 5.
We need the derivative of (3.39) with respect to Θ in applying HMC. The

















where θi is one of the variables in Θ.
Comparing the two MCMC methods (Gibbs sampling and HMC method) that
is to be used in the Gaussian Processes for a full MCMC treatment, a complete
Gibbs sampling scan takes a shorter time than the HMC updating of the hyper-
parameter (Neal, 1997). This is mainly because the sampling based on condition
probability is readily available. However, HMC is required to solve an inverse
matrix problem (refer to 3.41), which takes much longer time to solve. Therefore,
it is more sensible to have a few Gibbs samplings scans for each HMC sampling
in the program, as this probably makes the Markov chain mix faster.
Another issue is why we need two stages instead of one. Firstly, as mentioned
above, a two-stage process is faster than one-stage process, if we use purely HMC
sampling. This is mainly due to the matrix inversion. Secondly, the condition
probability of all latent functions and hyper-parameter is not available. Thus, we





Recently developed methods for monitoring mRNA expression changes involve
Microarray technologies. The technologies are powerful as they allow us to quickly
observe the changes at the differential expression levels of the entire complement of
the genome (cDNA) under different induced conditions. It is believed that under
these different conditions, how a gene or a set of genes expressed will provide
important information and clues to their biological functions.
Due to the large amount of data being produced, it is difficult to analyze
the data manually. Recognizing this problem, researchers have applied machine
learning techniques to help them interpret the data (Alizadeh et al., 2000; Alon
et al., 1999; Brown et al., 2000; Golub et al., 1999; Hvidsten et al., 2001).
In this chapter, we will discuss the microarray datasets used in the experi-
ments. The background of the microarray technologies will be described briefly,
and followed by the details of the datasets.
4.1 DNA Microarrays
A gene is a segment of the deoxyribonucleic acid (DNA) and it codes for a particu-
lar protein. A DNA molecule is a double stranded polymer made up of nucleotides.
Each nucleotide comprises a phosphate group, a deoxyribose sugar, and one of the
four nitrogen bases. The four different bases are adenine (A), guanine (G), cy-
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tosine (C), and thymine (T). The two stranded polymers are held by hydrogen
bond between nitrogen bases. The bases occur in pairs, with G pairing with C,
and A pairing with T. The particular order of the bases specify the exact genetics
instructions required to create organism.
Within each DNA molecule contains many genes, which carry the information
required for constructing proteins. The protein-coding instruction from the genes
are transmitted indirectly through messenger ribonucleic acid (mRNA), a transient
intermediary molecule that has a single stranded complementary copy of the base
sequence in the DNA molecule, with the base uracil (U) replacing thymine. The
process during which DNA is transcribed to mRNA is transcription. Then, it will
be translated to protein through translation process. To date, attention is mainly
on expression level at mRNA level. Microarray uses complementary DNA (cDNA),
which is produced from mRNA through reverse-transcription, to understand the
expression level of genes. Hybridization between these nucleic acids provides a
core capability of molecular biology (Southern et al., 1999).
Base-pairing (that is, A-T and G-C for DNA while A-U and G-C for RNA as
mentioned above) or hybridization is the underlining principle of DNA microarray.
A microarray is an orderly arrangement of samples. It provides a medium for
matching known and unknown cDNA samples based on base-pairing rules and
automating the process of identifying the unknowns. An microarray experiment
can make use of common assay systems (e.i. Gene Chip) and can be created
by hand or by robots that deposit the sample. In general, sample spot sizes in
microarray are typically less than 200 microns in diameter and each microarray
usually contains thousands of spots. Microarrays require specialized robots and
imaging equipment that generally are not commercially available as a complete
system.
DNA microarray, or DNA chips are fabricated by high-speed robots, generally
on glass but sometimes on nylon substrates, for which probes with known identity
are used to determine complementary binding, thus allowing massively parallel
gene expression and gene discovery studies. An experiment with a single DNA
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chip can provide researchers information on thousands of genes simultaneously.
There are different types of microarray technologies. We will discuss two of
them (which are cDNA microarrays (DeRisi et al., 1997; Duggan et al., 1999;
Schena et al., 1995) and high density oligonucleotide arrays (Lipshutz et al., 1999;
Loackhart et al., 1996)), from which datasets used in the experiments are pro-
duced.
4.1.1 cDNA Microarrays
Fabrication of microarrays begins with choosing the probes1 to be printed on
the microarrays. The specific genes of interest will be obtained and amplified.
Then, cDNA microarray are produced by spotting the amplified products onto
the matrix. Following purification and quality control to remove unwanted salts
and detergents, aliquots in term of nanoliters of purified products are printed on
coated glass microscope slides (chips) . The printing is carried out by a computer
controlled, high speed robot, with a “spotter” which is essentially a capillary tube.
The targets for the microarrays are obtained from reverse transcription of
mRNA pools. However, a labelling is done on the total RNA to maximize the
amount of message that can be obtained from a given amount of tissues. Fre-
quently, Cye3-dUTP (green) and Cye5-dUTP (red) are used for this fluorescent
labels, as they have relatively high incorporation efficiency with reverse transcrip-
tase and widely separated in their excitation and emission spectra. For example,
test targets are labelled with Cye5 and reference targets are labelled with Cye3.
The fluorescent targets, both test and reference, are pooled and allowed to
competitively hybridize to the probes on the chips, under stringent conditions.
During hybridization, the targets will interact with probes. If there is an interac-
tion, single strands from targets and the single strand of the cDNA will combine
and the targets will stick onto the immobilized probes, binding the targets to the
microarrays. In other words, such binding means that the gene represented by the
1a ”probe” is the tethered nucleic acid with known sequence, whereas a ”target” is the free
nucleic acid sample whose identity/abundance is being detected(Phimister, 1999)
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probe is active, or expressed, in the sample. (This is why the final results (images)
are actually the expression levels of the genes).
After hybridization process, the remaining solution that contains the targets
will be discarded and microarrays will be gently rinsed. The chips will then be
placed in a scanning confocal laser microscope. Laser excitation of the targets will
give an emission with a characteristic spectra. Genes expressed in common by both
test and reference targets will fluoresce with both colors, represented as yellow.
Those represented only in the test targets fluoresce red, and those represented in
the reference targets fluoresce green. The fluorescence intensity is reflecting the
cDNA expression level from both targets. In this case, if green color is observed,
we can claim that there is a reduction in expression and if red color is observed, it
means there is an increase of expression. So, to show the relevant individual gene
expression level, the ratio of test fluorescence intensity to reference (Cye5/Cye3)
can be used.
With that, we will be able to obtain images from the scanner. These image
data are then used for further analysis.
4.1.2 High Density Oligonucleotide Microarrays
High Density Oligonucleotide Microarrays synthesize oligonucleotides in situ as its
probes, instead of obtaining the probes from natural organism like cDNA microar-
rays. That is the main difference between these two methods.
We will focus on the GeneChipr, a microarray chip produced by Affymetrix.
The focus of the synthesis is light-directed. This involves two robust and unique
techniques which are photolithography and solid phase DNA synthesis. The fab-
rication of the Genechipris shown in Figure 4.1.
Photolithography allows the construction of arrays on rigid glass. Light is
directed through a mask to de-protect and activate selected sites, and protected
nucleotides couple to the activated sites. The process is repeated, activating dif-
ferent sets of sites and coupling different bases. In Figure 4.1, T is first nucleotides
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Figure 4.1: A unique combination of photolithography and combinatorial
chemistry to manufacture GeneChiprmicroarrays in Affymetrix. Adapt from
http://www.affymetrix.com/ technology/manufacturing/index.affx
introduced to the particular spot, and C is the second ones. In the end, this com-
bination of methods will be able to synthesize a type of complementary probe,
which consists of thousands of oligonucleotide probes for a single gene, at each
spot on the chip.
The population of cells that one wishes to analyze will be treated similarly in
that of cDNA microarray. The mRNA will be acquired from cells to be inves-
tigated. By reverse transcription, cDNA will be obtained. And, again, dye like
Cye3-dUTP and Cye5-dUTP can be used to label the test targets and reference
targets. These targets will be pooled and washed over the microarray. Whenever
the probes interact with cDNA strand through hybridization, the cDNA will bind
to the spot.
The microarrays is then scanned optically. And similar to cDNA microarrays,
different fluorescent colors are the indications of the expression levels of genes.
The relative expression levels between the test and reference targets can be found
using the ratio of red to green.




Microarrays often consist of thousands of probes, and there is a chance that some
of the probes will be poor representation of genes. Worse, these probes often play a
major part in the increment or decrement of expression levels in microarrays. Take
note that the poor representation is more severe in cDNA microarrays technology
as High Density Oligonucleotide microarrays have much higher quality control
during the fabrication of the chips. This contributes to the major cause of noise
in the data. Besides, different technological factors (such as machine setting and
saturation settings) and different experiment procedures (such as time taken for
aliquot quantities) as well as human errors may cause variability in the data.
Much research and effort have been done to reduce the variability. Much
of the literature addressing microarray normalization concerns cDNA microarray
data, whereas only a few examples can be found for oligonucleotide microarrays.
Workman et al. (2002) have done a short review on microarray normalization
techniques.
Basically, the normalization methods are microarrays techniques dependent.
Since our focus is on the classification and feature selection, we do not address
normalization problem. However, it is observed that by applying normalization
in two directions, i.e. normalization on all the gene expressions of each exam-
ple, and then, another normalization process in done along the genes, gives good
classification results. The reason is, though, not known to us.
4.3 Datasets
It is believed that gene expressions are essential for obtaining comprehensive pic-
tures of the functioning of cell. Understanding the relative changes among the
thousands of genes will be impossible without the careful use of some genome
analysis. Microarrays have provided a tool to record the activities of these genes
in parallel. It is hope that through this tool that the key players are able to be
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recognized. For example, a design to identify new disease classes may also reveal
clues about the basic biology of disorders from the microarrays data, and may
suggest novel drug targets. This has motivated researchers to collect and study
the microarrays data, based on this idea (Alizadeh et al., 2000; Alon et al., 1999;
Golub et al., 1999; Perou et al., 1999; Pollack et al., 1999; Ross et al., 2000).
In this section, we will discuss four microarrays datasets that are used in this
project.
4.3.1 Breast Cancer Dataset
This datasets was obtained by West et al. (2001). The dataset is based on breast
tumor samples from the Duke Breast Cancer SPORE frozen tissue. There are
two problems that are solved by (West et al., 2001). They are the classification
of estrogen receptor (ER+/-ER) and classification of lymph node (LN+/LN-). In
this project, we only focus on classifying between ER+ and ER-.
There are originally 49 tumor cases. However, West et al. (2001) have observed
that in five tumor sample cases, the classification results are inconsistent. There-
fore, we only used 44 examples in our experiment, consisting of 23 ER+ cases and
21 ER- cases. The number of gene representing each example is 7129. There is no
missing data in this dataset.
The dataset is available at http : //mgm.duke.edu/genome/dna micro/work/.
This dataset is obtained using Affymetrix GeneChipr. The targets and chips
were hybridized at 450C for 16 hours. After that, the chips were scanned with
GeneChiprscanner to obtained the signal.
4.3.2 Colon Cancer Dataset
Alon et al. (1999) have used Affymetrix GeneChipr to find the expression level of
genes from colon adenocarcinoma specimens. From some of patients whom these
specimens are found, normal colon tissue was also obtained. mRNA was then
extracted from these tissue and hybridized to the GeneChipr. Images (i.e. data)
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are obtained after the scanning. Thus, the task is to identify tumor from normal
tissues.
The data consist of 22 normal tissues and 40 cancer tissues. For each tissue
(example), there are around 6000 genes originally. Alon et al. (1999) has selected
2000 genes, where some genes are non-human genes. The dataset is available at
http : //lara.enm.bris.ac.uk/colin/.
4.3.3 Leukaemia Dataset
Leukaemia dataset from Golub et al. (1999) is to distinguish acute myeloid leukaemia
(AML) from acute lymphoblastic leukaemia (ALL). The original datasets consist
of both training and testing data, 27 ALL and 11 AML samples for training data
and 20 ALL and 14 AML for testing data. In this project, we combine both data
as the learning samples are not sufficient. In all samples, there are 7129 genes.
The dataset can be obtained from http : //lara.enm.bris.ac.uk/colin/.
This dataset is obtained through High Density Oligonucleotides microarrays
(Affymetrix). And the targets are prepared from bones marrow samples from
patients with acute leukaemia.
4.3.4 Ovarian Cancer Dataset
Schena et al. (1995) have used cDNA microarrays techniques to obtained Ovarian
cancer. Ovarian cancer dataset consists of 24 normal and 30 cancer tissues. There





Gaussian Processes are used as classifiers and feature selection tools in this thesis.
Before applying on Microarray data, experiments were conducted to gain a better
understanding on the method and its implementation.
In this chapter, we discuss the experiments done to identify the onset of equi-
librium state for the MCMC sampling. After that, we will discuss the effect of
gamma distribution of Θ (3.40).
5.1 Understanding on Gaussian Processes
5.1.1 Banana Dataset
To gain more insight into the implementation issues of Gaussian Processes, a
simple dataset is used. For this purpose, we use the banana dataset. The dataset
can be obtained at http : //mlg.anu.edu.au/ ∼ raetsch/data/. This dataset
contains 400 training and 4900 testing examples. There are only 2 features, with
1 output for each example. The output is binary while the input is continuous,
with zero mean and standard deviation of one. There is no missing data in this
dataset.
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Figure 5.1: Values of Θ for original Banana datasets. Values on the vertical axis
is the values of Θ while the horizontal axis is the iteration number of the values
of Θ.
5.1.2 ARD at work
We created two irrelevant features using data from a zero mean Gaussian distri-
bution with standard deviation of one. For the first run, we used the original
training data with these 4 features for training and testing.
From Figure 5.1, we observe that the ARD values (which is the Θ variable) re-
mained at a certain level. This shows that the ARD is able to identify the relevant
features from irrelevant features, through iteration of samplings. Another point,
observed from the results, is that there is a strong evidence of the state of invariant
distribution. We will not be able to observe such a systematic characteristics if
the invariant distribution is not reached.
Having observed the effect of irrelevant features, let us discuss the redundant
features. In addition to the irrelevant features created above, we created two
additional features that are exact duplicate of the original two features. These
two features are therefore redundant. In total, six features are present for each
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example.
For our study, we group the 400 training examples and 4900 testing examples
into one dataset. Data from this dataset is then divided into three categories,
based on the variance of the P (t(x∗) = +1|T ) over MCMC samples. The first
category consists of examples that are easy to be classified. For each example
in the first category, P (t(x∗) = +1|T ) over the MCMC samples is small. This
means that the examples of the first category are clearly from one class (i.e. the
P (t(x∗) = +1|T ) is close to 1 or 0). The second category consists of examples that
are moderate in terms of the difficulty of classification and last category consists
of examples that are difficult to classify. Similarly, the way to decide the difficulty
depends on the variance of the P (t(x∗) = +1|T ) over the MCMC samples.100
examples are chosen for the dataset to form the training data. In this 100 training
examples, equal number for each categories were present.
In Figure 5.2, the entire dataset is shown using the original two features. In
Figure 5.3, 100 training examples are shown with “¤” being of class 1 and “♦”
being of class 2. From the figure, we can see the training examples chosen are
representative of the whole dataset.
In addition to the 100 training examples, some examples are also selected for
original dataset for detailed study. The location of these selected data are shown
as “o” and “*” in Figure 5.4. Again, these selected examples have varying level of
difficulties.
During the training process, the typical variation of Θ values over the MCMC
samples are shown in Figure 5.5. We can observe that the values of the features,
in particular, the relevant feature and its redundant feature interchange in values.
For example, in Figure 5.6 (which is a zoom-in figure of Figure 5.5 around 170
to 190 iterations), before iteration 183, “redundant 2” feature is identified as the
important feature while “relevant 2” feature is not. After iteration 183, “relevant
2” feature is identified as the important feature while “redundant 2” feature is
not. This is expected. The Θ values of the features indicated the importance
of the features in the evidence space. When Θ values of the relevant feature is
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original class 1 example
original class 2 example
Figure 5.2: Location of all the original examples in the feature space.
high, Θ values of the redundant feature goes low and vice verse. As a result, the
value of Θ interchange periodically, depending on the samples locations chosen by
the MCMC procedure. In this case, the distribution of the hyper-parameter is
like having four humps in the hyper space. This provides a strong evidence that
equilibrium state is reached.
5.1.3 Equilibrium State
For six features for our banana dataset, equilibrium states can be monitored by
examining pairs of Θ along the iteration. However, it will be almost impossible to
observe such pattern with the data have than 10 features, let alone thousands of
features as in Microarray datasets. The values of Θ are hard to monitor. Inter-
changing of the values of Θ is even harder to observe in such a high dimensional
feature space. Therefore, we would like to propose another way to detect the onset
of equilibrium state, based on the posterior probability, P (t(x∗) = +1|T ), as given
by (3.14). Naturally, under the Bayesian framework, P (t(x∗) = +1|T ) will not be
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original class 1 example
original class 2 example
selected class 1 training data
selected class 2 training data
Figure 5.3: Location of all the training examples in the feature space.
the same over every iteration of the MCMC samples. However, it is expected that
the median and/or the mean of P (t(x∗) = +1|T ), based on some fixed number of
iterations, will be consistent once equilibrium state is reached. Example of this
fact is shown in Figures 5.7 and 5.8, where the median of P (t(x∗) = +1|T ) over
25 MCMC samples (box plot) is drawn. Box plot is a box, which has lines at the
lower quartile, median, and upper quartile values.
From Figure 5.5, we observe that the ARD values shows that equilibrium state
is reached after about 80 iterations. And from Figure 5.7 and Figure 5.8, we also
notice that the median of P (t(x∗) = +1|T ) becomes consistent from the 4th box
onward (which is 75th iteration onward).
The box plots gives in Figure 5.7 and Figure 5.8 are drawn from examples that
are easy to classify (referring to Figure 5.4). These two examples are situated in
the midst of examples from the same class.
However, from Figure 5.9 and Figure 5.10 respectively, the examples lie at the
boundary of the two classes. In this case, the median of 25 iterations of P (t(x∗) =
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original class 1 example
original class 2 example
selected class 1 training data
selected class 2 training data
selected class 1 testing data for detailed study
selected class 2 testing data for detailed study
Figure 5.4: Location of all training and testing examples in the feature space.
+1|T ) is pretty consistent for the 4th box onwards, but the variance of the median
is much higher. This is again expected under the Bayesian framework. The values
of P (t(x∗) = +1|T ) vary to a greater extent when the example concerned is near
the boundary of the two classes.
Thus, with the observations above, we would use the median of P (t(x∗) =
+1|T ) over 25 samples as the criterion to determine the onset of equilibrium state.
The main reason, as mentioned, is that the values of Θ will be hard to monitor and
may take a longer time to observe equilibrium state due to its high dimensionality.
Also, we will not know the interaction (correlation) of the features (genes) most
of the time. The clear interaction which we created purposely in Banana dataset
may not be seen. Moreover, there are too many ARD values to monitor.
Now, by using the median of iterations of P (t(x∗) = +1|T ), we will be able
to identify the equilibrium state. However, there is still one question to answer.
How many iterations should be used for the final prediction of P (t(x∗) = +1|T ) as
given in (3.14)? From the experiment above, it seems to be safe to use the same
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Figure 5.5: Values of Θ for Banana datasets, with redundant features.
number of iterations of which the samplings reach the equilibrium state. We can
lengthen the run to increase the “safety factor”.
All the box plots of the 18 testing examples can be found in Appendix A.
5.1.4 Effect of Gamma Distribution
From equation (3.40), gamma distribution is used as the prior distribution for each
hyper-parameter (3.40). However, we have faced some problems in deciding the
values of these parameters, i.e. a and b (3.40).
Based on our experiments, the “wrong” choice of prior distribution can stop
the MCMC sampling prematurely. Till now, we are still not sure of the main cause
of this problem. However, it is observed that some choices of the prior distribution
will cause the HMC to reject many candidates, resulting in the large values of Θ.
The “wrong” prior distribution may also fail to find values of Θ giving a sign of
equilibrium state (refer to Figure 5.11). There is no clear crossing between relevant
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Figure 5.6: Values of Θ for Banana datasets, with redundant features.
and redundant features. When we repeat the banana experiment, for some prior
distributions, we can’t observe the presence of equilibrium state even after 10000
iterations. Also, none of the median of P (t(x∗) = +1|T ) has stabilized.
This is something that is still not being understood fully. What we have done
to overcome the problem is simply to identify a prior distribution which avoid such
scenario.
5.1.5 Summary
We have proposed a way to determine the onset of equilibrium state in MCMC
samplings. This criterion is used for all other experiments in the subsequent data
of this thesis.
The median of the posterior probability of an arbitrary iteration will be found
for each example, using box plot. The point at which the median of the predicting
probability remain consistent (±0.15) will be identified as the point where the
samplings reach equilibrium state.
Besides, it is also a must to make sure that majority of the examples gives a
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Figure 5.7: Box plot of testing example 4184 along iteration of MCMC samplings.
Values on the vertical axis is the values of Θ while each column represents 25
iterations of the values of Θ.












Figure 5.8: Box plot of testing example 864 along iteration of MCMC samplings.
Values on the vertical axis is the values of Θ while each column represents 25
iterations of the values of Θ.
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Figure 5.9: Box plot of testing example 2055 along iteration of MCMC samplings.
Values on the vertical axis is the values of Θ while each column represents 25
iterations of the values of Θ.

















Figure 5.10: Box plot of testing example 4422 along iteration of MCMC samplings.
Values on the vertical axis is the values of Θ while each column represents 25
iterations of the values of Θ.
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Figure 5.11: Values of Θ for Banana datasets, with prior distribution that fails to
work. Only last 500 is shown here.
confident prediction (more than 0.7 or less than 0.3). This is to avoid the problem
of using a “wrong” prior distribution of hyper-parameter.
Besides the implementation issues, we also tried to explore the possibility of
applying Principal Component Analysis on the values of Θ. However, no concrete





In this chapter, we will discuss the methodology for feature selection and then
testing of the accuracy of the feature selection process. The testing is used for
the evaluation of Gaussian Processes as a classifier for DNA Microarray datasets
while ARD is the feature selection method.
We have made use of k-fold cross validation to evaluate the algorithm of the
classifier. Basically, this re-sampling method splits the data into k folds. During
each training process, k−1 folds will be used as training data while the remaining
one fold will be used as testing data. The training process repeats k times so that
all the folds have become testing data exactly once. The testing accuracy given
by each training process will be the validation accuracy.
6.1 Feature Selection
For the purpose of feature selection, we use a routine, which we call Procedure
Cross Validation, PCV(D,l), where D is the data used as the input to the routine
and l is the number of feature returned as the output of the routine.
The PVC(D,l) routine does the following:
1. Stratify the data, D, into m folds. Each time one fold, i, is used as the
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testing data while the remaining, D−i, is used as the training dataset.
2. Apply filter method, either Information Gain and Fisher Score on D−i.
Based on the measure used for the filter method, the top 100 features are
chosen.
3. D−i with only these top 100 features are used as training data in Gaussian
Processes. Compute E(Θ|D−i) (as in (3.18)) and come up with a ranking of
the genes ordered by their respective Θ values.
4. Let j = 1. Select the top j genes based on the ranking of Θ obtained from
step 3. Compute the number of correctly classified data as nji for all data
points in fold i (the testing data). Here, each data point in fold i is only
represented by the top j genes.
5. Repeat step 4 by increasing j by 1 till j = 100.
6. Repeat step 2 to 5 over the m folds. In so doing, obtain the number of cor-




i for j = 1, . . . , 100.
7. The number of genes with the best cross-validation accuracy is denoted by
l, i.e. l = argmaxAj, where Aj = n
j
‖D‖ .
With that, we have completed the m-fold cross validation process (let’s call it
internal cross validation). From the test accuracy of the m-fold cross validation,
we will be able to know the optimal features to be used.
6.2 Unbiased Test Accuracy
In view of the small number of training data, it is important to assume that bias is
not introduced . Based on the discussion of Ambroise and McLachlan (2002), we
have designed a procedure to find the unbiased test accuracy of Gaussian Processes
as a classifier.
The following external cross-validation procedure is used:
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1. Stratify the data into p folds. Each time one fold, k, is used as the testing
data while the remaining, D−k is used as training dataset.
2. Invoke PCV(D−k,l).
3. Using the number l returned from PCV(D−k,l)from step 2, compute the
testing accuracy on the k fold (the testing fold).
4. Repeat steps 2 and 3 for k = 1, . . . , p.
5. Unbiased testing accuracy will be obtained based on the results from steps
1 to 4.
To avoid long search, we use p=3 and m=3 for all the experiments. If time is
allowable, p=10 and m=10 is advisable. A three-fold cross validation uses at least
five times shorter the time than a ten-fold cross validation will take.
6.3 Performance Measure
In step 4 of the PCV(D,l) routine, the performance of the Gaussian Processes
is measured by nj, where nj is the number of correctly classified data in the
testing data. Other measures exist to infer the performance of Gaussian Processes.
Using the number of correctly classified data does not capture the confidence
of a particular prediction. In this section, we introduce two other measures of
performance for the purpose. Table 6.1 gives the three measures of performance.
Table 6.1: Three Measure of Performance
PM1 Test Accuracy
PM2 Negative Logarithm Likelihood
PM3 Negative Logarithm Likelihood (iteration)
Firstly, we will use the mean of the posterior probability (3.14). When the true
label is 1, and if the mean of posterior probability is more than 0.5, the example
is correctly classified. Then the summation is added by 1. When the true label is
0, and if the mean of posterior probability is less than 0.5, the example is again
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correctly classified. Then, the summation is added by 1. However, if the true label
is 1 and the mean of posterior probability is less than 0.5, the example is wrongly
classified. Then there is no addition. Similarly for the case when the true label is
0 and the mean of posterior probability is more than 0.5. Mathematically, this is
shown in (6.1).




max〈sign[(P (t(xi) = +1|T )− 0.5)× t˜i], 0〉 (6.1)
where t˜i is the true label, taking values 1 or 0, and N is the number of testing
examples.
We also use negative logarithm likelihood as measure. Assuming that all the
testing examples are independent, we can find the likelihood using (6.2). This is
to make use of the probabilistic modelling of Gaussian Processes. In this case,
mean of the posterior probability is used. By using negative logarithm likelihood,
we have include more information, especially the confident level of the prediction.
However, unlike test accuracy, the value of equation (6.2) is used for comparison.
The value by itself does not carry much meaning. For example, we will know how
many examples are predicted correctly by checking equation (6.1), but we are not





log{(P (t(xi) = +1|T )t˜i(1− (P (t(xi) = +1|T ))1−t˜i} (6.2)
The last method is based on all the predicting probabilities of all iterations that
are sampled from equilibrium distribution. And for each iteration, we will find
the negative logarithm likelihood as (6.3). So, we can take (6.3) as the expected
negative logarithm likelihood. Like (6.2), (6.3) is used for comparison among all
the other (6.3). The value by itself does not carry much meaning.
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log{Pj(t(xi) = +1|T )t˜i(1− Pj(t(xi) = +1|T )1−t˜i} (6.3)




This chapter discusses the results obtained based on the methodology mentioned
in section 6. They include discussion on the performance of Gaussian Processes
as the classifier and then the genes selected by ARD. The notations used follow
the previous chapter if not re-defined.
7.1 Unbiased Test Accuracy
This section presents the results based on the methodology mentioned in Section
6.2. The performance measurement is based on the discussion in Section 6.3. For
notation, the definition used follows Section 6.2 if it is not defined in this section.
The results of applying the unbiased test accuracy methodology are given in
Table 7.1 to Table 7.8 for the four datasets which are Colon Cancer, Breast Cancer,
Leukaemia and Ovarian. They also differ in terms of the initial feature selection
method. Only the optimal number of features (as in l in routine PVC(D,l)) in
the internal cross validation is presented here. Based on the optimal number of
features in the third column, we obtain the average unbiased test accuracy, given
in the fourth column. Note that PM1, PM2 and PM3 are used for the PCV
routine. The external cross-validation process has only PM1.
From Table 7.1, Table 7.3 and Table 7.4, values of PM1 of the three internal
cross validation show some variation. One possible reason for this could be the
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Table 7.1: Results of the unbiased test accuracy methodology for Breast Cancer
Dataset-Fisher Score and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy












Table 7.2: Results of the unbiased test accuracy methodology for Breast Cancer
Dataset-Information Gain and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy













Table 7.3: Results of the unbiased test accuracy methodology for Colon Cancer
Dataset-Fisher Score and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy












Table 7.4: Results of the unbiased test accuracy methodology for Colon Cancer
Dataset-Information Gain and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy













Table 7.5: Results of the unbiased test accuracy methodology for Leukaemia
Dataset-Fisher Score and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy












Table 7.6: Results of the unbiased test accuracy methodology for Leukaemia
Dataset-Information Gain and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy













Table 7.7: Results of the unbiased test accuracy methodology for Ovarian Cancer
Dataset-Fisher Score and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy












Table 7.8: Results of the unbiased test accuracy methodology for Ovarian Cancer
Dataset-Information Gain and ARD
Internal Cross Number of Performance Overall Unbiased
Validation Run Features Test Accuracy













use of small number of folds in the cross validation process.
We can also observe that the average test accuracy (fourth columns of tables)
differs from each internal cross validation (third columns of tables). Again, this
may be due to the small number of folds and examples available. There is a high
chance that the data is split into the folds non-uniformly. As a result, training
process of the classifier during internal cross validation fails to learn such cases.
The problem can be overcome if we use ten-fold cross validation or leave-one-out
cross validation.
Generally, PM1 performs well compared to the other two measurements. Thus,
for feature selection and other comparisons, we will mainly use the results based
on PM1 as performance measurement.
We will compare the average unbiased test accuracy mainly with Shevade and
Keerthi (2002) as it also used average test accuracy for unbiased estimation of the
classifier performance.
Table 7.9: Comparison for different dataset with the Sparse Logistic Regression
method of Shevade and Keerthi (2002)
Data set Sparse Logistic Regression Fisher Score and ARD Information and ARD
Breast Cancer 81.2% 84.09% 84.09%
Colon Cancer 82.3% 80.65% 87.10%
Leukaemia 93.1% 77.78% 68.00%
Ovarian Cancer 83.3% 70.37% 79.63%
From Table 7.9, ARD with Information Gain performs competitively in Breast
Cancer, Colon Cancer and Ovarian Cancer datasets, while ARD with Fisher Score
works well in Breast Cancer, and Colon Cancer dataset.
We also compare the methodology with Long and Vega (2003) who used Boost-
ing method to obtain cross validation estimates. There are eight algorithms used
by Long and Vega (2003). Three of six datasets, i.e. Breast Cancer, Colon Cancer
and Leukaemia, used by Long and Vega (2003) are compared. Since Long and
Vega (2003) set gene limit to ten and hundred, we will do the same using our
methodology. In step 4 in PCV routine, j is fixed at 10 (i.e. j = 10).
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Table 7.10: Comparison for different dataset with Long and Vega (2003) with gene
limited at 10
Algorithm Breast Cancer Colon Cancer Leukaemia
Fisher Score with ARD 77.3% 83.9% 79.2%
Information Gain with ARD 79.5% 87.1% 62.5%
Adaboost 80.1% 74.7% 93.8%
Adaboost-VC 81.9% 75.6% 96.1%
Adaboost-NR 80.5% 74.9% 94.0%
Adaboost-PL 79.4% 76.6% 93.0%
Arc-x4-RW 80.2% 75.0% 91.8%
Arc-x4-RW-NR 82.2% 75.3% 96.7%
SVM-RFE 79.1% 80.8% 86.6%
Wilcoxon/SVM 76.8% 75.7% 93.6%
As we have observed previously, the methodology we use performs poorly for
Leukaemia dataset compared with the other algorithms, especially Information
Gain with ARD. However, for the other two datasets, the methodology shows
very competitive results. For Colon dataset in particular, the average accuracy is
larger than that of other algorithms.
Another point that needs clarification is that we expect that the results of our
methodology shown in Table 7.9 should be similar to, if not better than, that of
Table 7.10. The reason is because we consistently look for the optimal number
of features in the former experiment. However, for some of the cases, it is not
so. Again, we think that this is due to the three-fold cross validation and the low
number of features available. The problem will most probably be solved if ten-fold
cross validation is used.
From the discussion above, we can see that the methodology using filter meth-
ods with ARD is competitive and giving comparable results with other algorithms.
If time is allowable, ten-fold cross validation can be used for better confident level
as well as more “stable” results.
7.2 Feature Selection
From the results in section 7.1, we make use of two results which we apply in
feature selection process.
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1. The measurement for performance will be based on the test accuracy (that
is PM1).
2. Certain combinations of feature selection methods are applied on different
datasets, as shown in Table 7.11.
Table 7.11: Feature selection method used in different dataset
Dataset Feature Selection Method
Breast Cancer Both Combinations
Colon Cancer Information Gain with ARD
Leukaemia Fisher Score with ARD
Ovarian Cancer Information Gain with ARD
And, Table 7.12 shows the number of genes that give best performance based
on the feature selection process discussed in section 6.1.
Table 7.12: Optimal number of features on different dataset
Dataset Optimal Number of Feature
Breast Cancer (Fisher Score with ARD) 12




Table 7.13: Selected genes for the breast cancer based on fisher score with ARD
ID Gene Annotation
6484 H.sapiens mRNA for cathepsin C
1376 Guanosine 5’ -Monophosphate Synthase
709 Human mRNA for KIAA0182 gene, partial cds
1488 Human transforming growth factor-beta 3 (TGF-beta3) mRNA, complete cds
4234 Human splicing factor SRp40-3 (SRp40) mRNA, complete cds
2159 Homo sapiens (clone zap128) mRNA, 3’end of cds
4 Human mRNA for semaphorin E, complete cds
6917 H.sapiens kinectin gene
1095 Tyrosine Kinase
822 Human mRNA for KIAA0232 gene, complete cds
1512 Y box binding protein-1 (YB-1) mRNA
1505 Human microtubule-associated protein tau mRNA, complete cds
Comparing the results of Shevade and Keerthi (2002), all the top six genes that
were selected by Shevade and Keerthi (2002) appear in Table 7.13, while three out
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Table 7.14: Selected genes for the breast cancer dataset based on Information
Gain with ARD
ID Gene Annotation
6484 H.sapiens mRNA for cathepsin C
1881 Human high mobility group protein (HMG-I(Y)) gene exons 1-8, complete cds
1376 Guanosine 5’ -Monophosphate Synthase
4234 Human splicing factor SRp40-3 (SRp40) mRNA, complete cds
2159 Homo sapiens (clone zap128) mRNA, 3’end of cds
3464 L-arginine:glycine amidinotransferase [human, kidney carcinoma cells, mRNA, 2330 nt]
2779 Human omega light chain protein 14.1 (Ig lambda chain related) gene
1512 Y box binding protein-1 (YB-1) mRNA
4629 Human leukotriene C4 synthase (LTC4S) gene, complete cds
4169 Human p16INK4/MTS1 mRNA, complete cds
1025 Major Intrinsic Protein
3998 Human TFIID subunit TAFII55 (TAFII55) mRNA, complete cds
1999 Human autoantigen pericentriol material 1 (PCM-1) mRNA, complete cds
5642 Human CD14 mRNA for myelid cell-specific leucine-rich glycoprotein
362 Human mRNA for platelet-type phosphofructokinase, complete cds
of the six genes appeared in Table 7.14 ( which are gene ID 6484, 4234 and 1512).
In West et al. (2001), there are 40 genes listed. Only 2 (gene ID 6484 and 1505)
and 1 (gene ID 6484) genes found in Table 7.13 and Table 7.14 respectively.
Table 7.15: Selected genes for the colon cancer dataset based on Information Gain
with ARD
ID Gene Annotation
377 H.sapiens mRNA for GCAP-II/uroguanylin precursor
493 MYOSIN HEAVY CHAIN, NONMUSCLE (Gallus gallus)
1423 MYOSIN REGULATORY LIGHT CHAIN 2, SMOOTH MUSCLE ISOFORM (HUMAN);
contains element TAR1 repetitive element
1325 S-100P PROTEIN (HUMAN)
14 MYOSIN LIGHT CHAIN ALKALI, SMOOTH-MUSCLE ISOFORM (HUMAN)
765 Human cysteine-rich protein (CRP) gene, exons 5 and 6
627 H.sapiens mRNA for protein tyrosine phosphatase
Comparing Table 7.15 and results from Shevade and Keerthi (2002), there are
only two genes in common, which are gene ID 377 and 493. These two genes
appear to be the top two genes given by our methodology. Same two genes are
also mentioned in Li et al. (2001b). Of the 50 genes listed in Bo and Jonassen
(2002) who evaluate genes in pairs, all the top 7 genes are included. However,
none of the gene is in common with the 7 genes selected by Guyon et al. (2002).
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2238 GATA2 GATA-binding protein 2
4142 CD37 CD37 antigen
2402 Azurocidin gene
2641 Fetal Alz-50-reactive clone 1 (FAC1) mRNA
5352 GB DEF = Nonmuscle myosin heavy chain-B (MYH10) mRNA, partial cds
5402 E2F5 E2F transcription factor 5, p130-binding
6134 GB DEF = Clone 110298 map Xq28, mRNA sequence
2242 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE, MITOCHONDRIAL PRECURSOR
2626 MSH2 DNA repair protein MSH2
2056 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)
5418 DNA-dependent protein kinase catalytic subunit (DNA-PKcs) mRNA
3258 Phosphotyrosine independent ligand p62 for the Lck SH2 domain mRNA
The genes given in Table 7.16 do no coincide with that of Shevade and Keerthi
(2002), Guyon et al. (2002), Li et al. (2001b) nor Szabo et al. (2002).
Table 7.17: Selected genes for the ovarian cancer dataset based on fisher score
with ARD
ID 687 1526 1491 1028 93 1419 658 1387 1117 1512 596 47
Of the 12 genes mentioned in Table 7.17, gene ID 1526 and 93 are considered
important features of algorithm 1 in Li et al. (2001b) and gene ID 1526 and 1491
are considered important features of algorithm 2 in Li et al. (2001b). Comparing
with Shevade and Keerthi (2002), gene ID 1526 and 1387 are the common features.
From the results of the feature selection process, we can observe that gene





In this thesis, we have used ARD as the feature selection tool for DNA microar-
ray data. In the probabilistic framework of Gaussian processes along with ARD
parameters, we apply the external cross validation methodology. Based on the
design, we have observed competitive results. Except the Leukaemia dataset, the
results of the other three datasets show that the methodology perform closely with
the results of Shevade and Keerthi (2002). Also, we compare the genes selected
under the methodology with the rest of the literature. Again, we can see some of
the genes selected are in common (particularly Breast Cancer Dataset). It is the
aim of this project to highlight a small number of some genes (from thousands of
them) which the classifier (Gaussian Processes) and the methodology (Information
Gain with ARD and Fisher Score with ARD) have identified. We hope that this
will help the biologists shorten their time to find out the culprit of certain disease.
With the acquired knowledge gain, they may be able to develop procedures and
drugs to prevent diseases.
During the project, we also have gained better understanding on Gaussian
Processes. We have proposed the use of the median of posterior probabilities to
check whether the equilibrium distribution is reached. This is mainly due to a
lack of other methods to judge whether the samplings are done on equilibrium
distribution.
There are also many other ways to speed up the training process. In the soft-
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ware, there are different kinds of Monte Carlo Markov Chain methods to be used.
There are even a few versions of Hybrid Monte Carlo (HMC) which may improve
the sampling. For simplicity, the HMC that used in the project is mainly based on
Duan et al. (1987). However, different versions that speed up the attainment of
equilibrium state are available. Theoretically, any version used will still bring us
to invariant distribution. Further study could investigate which version of MCMC
sampling methods are more suitable for DNA Microarray datasets.
Another main question which remained unsolved is the choice of the prior
of hyper-parameters. From the observation and discussion in Section 5.1.4, it is
important to choose the right parameter for the Gamma Distribution. We believe
that these parameters are data dependent, especially the spreading of the values
of the features. However, further study is required to gain better understanding
in this matter.
Also, there are a few issues on the design of the methodology that we would
like to highlight. Firstly, we only use three-fold cross validation. However, in our
view, it is advisable to use ten-fold cross validation for both internal and external
cross validation. This will give results with higher confidence and accuracy. In
view of the small number of examples available, if the computation time and power
is not an issue, leave-one-out cross validation can be used too. Another concern
of using three-fold cross validation is the reproducibility of the results obtained in
this thesis. Again, this can be overcome by using a larger number of k-fold cross
validation.
We have employed Information Gain and Fisher Score as filter methods to
reduce the number of features largely. 100 features in this case was arbitrarily set.
Such a crude cut over the number of the features may be not optimal. However,
from the results (average test accuracy), the number seems to be a reasonable.
Moreover, the filter method used in this case does not seem to affect the final
results significantly. Nevertheless, in the future, if there is an indication that more
genes are required, we can use 200 features or more. The increase in the number of
features does require more time to do a MCMC samplings in Gaussian Processes.
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Figures for Banana Experiments
The figures are obtained for gaining a better understanding on Gaussian Process.
The detail of the experiments and the discussion can be found in Chapter 5.
The following is the locations the training examples and testing examples in
the two relevant features space.































original class 1 example
original class 2 example
selected class 1 training data
selected class 2 training data
selected class 1 testing data for detailed study
selected class 2 testing data for detailed study
Figure A.1: Location of training and testing examples in the feature space.
The followings are the figures that shows the box plot of the testing examples
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of interest. The vertical axis is the predicting probability of class 1. The horizontal
axis is the iterations. For each box plot, it represents 25 iterations.













Figure A.2: Box plot of testing example 3128 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.3: Box plot of testing example 864 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.














Figure A.4: Box plot of testing example 3752 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.5: Box plot of testing example 1171 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
















Figure A.6: Box plot of testing example 139 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.7: Box plot of testing example 4183 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
















Figure A.8: Box plot of testing example 829 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.9: Box plot of testing example 4422 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
















Figure A.10: Box plot of testing example 3544 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.11: Box plot of testing example 1475 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.













Figure A.12: Box plot of testing example 2711 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.13: Box plot of testing example 768 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.















Figure A.14: Box plot of testing example 576 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.15: Box plot of testing example 1024 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.














Figure A.16: Box plot of testing example 1238 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.17: Box plot of testing example 4184 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
















Figure A.18: Box plot of testing example 1746 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25
iterations of ARD values.
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Figure A.19: Box plot of testing example 2055 along iteration of MCMC samplings.
Values on the vertical axis is the ARD values while each column represents 25




What we have mentioned in section 6 is an unbiased design. However, before
coming out with the design, we have another methodology. From the results, we
realize that it is actually bias. This problem highlights the significance of selection
bias (Ambroise and McLachlan, 2002) in Microarray Dataset or any small dataset
where number of examples is small (less than 100 examples). We will briefly
discuss this in the following section.
B.1 Biased Test Accuracy
If the notation is not defined, we will follow the definition that used in section
6.2 to discuss this methodology. For this methodology, we are using ten-fold cross
validation. The data is split into 10 folders which are K1, K2,. . . , K10. For first
external cross-validation run, R1, we will have K1 as external testing data, and
the rest of the data (let us denote it as K−1)be the training data.
We apply filter method (information gain and fisher score) on the K−1 data to
choose 100 features (or a bit more if the score of features are the same). The chosen
100 features will be fed into Gaussian Processes to find the ranking of the features
based on ARD values. We will then split K−1 to ten folders for internal cross
validation. Thus, we will have k1, k2 . . . , k10. For first internal cross validation
run, r1, we will have k1 as internal testing data and the rest of the data (which
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is denoted as k−1) be the internal training data. And based on the ARD ranking,
we will have k1 with different number of features, from 5 features to 20 features.
Thus, after 10 internal runs (which are r1, r2, . . . , r10) of internal cross valida-
tion, we will obtain internal cross validation performance for different number of
features. Take note that for this methodology, the features of training and testing
data for all internal runs (r1 to r10) of R1 will be similar. In other words, train5 of
r1 will have the same features as train5 in r2. This is not the same as the unbiased
test accuracy methodology in section 6.2.
After R1, we will obtain an optimal number of feature. Based on this optimal
features, we will create testing and training data based on K1 andK−1 respectively.
This is repeated for different external cross validation runs (i.e. R2, to R10). With
the completion of the external cross validation, we will obtain a test accuracy. Take
notes that for each external cross validation run, we may have different optimal
features.
Table B.1: Results of the biased test accuracy methodology for Breast Cancer
Dataset-Fisher Score and ARD











External Cross Validation Test Accuracy
79.5
Table B.1 to Table B.8 show the results of the bias test accuracy methodology.
It can be observed that there are significant difference in all results of the internal
cross validation and the external cross validation. All the internal cross validation
are having a better accuracy than that of external cross validation. This is due to
the selection bias in the internal cross validation.
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Table B.2: Results of the biased test accuracy methodology for Breast Cancer
Dataset-Information Gain and ARD











External Cross Validation Test Accuracy
70.5
Table B.3: Results of the biased test accuracy methodology for Colon Cancer
Dataset-Fisher Score and ARD











External Cross Validation Test Accuracy
81.3
Table B.4: Results of the biased test accuracy methodology for Colon Cancer
Dataset-Information Gain and ARD











External Cross Validation Test Accuracy
80.6
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Table B.5: Results of the biased test accuracy methodology for Leukaemia
Dataset-Fisher Score and ARD











External Cross Validation Test Accuracy
66.7
Table B.6: Results of the biased test accuracy methodology for Leukaemia
Dataset-Information Gain and ARD











External Cross Validation Test Accuracy
72.2
Table B.7: Results of the biased test accuracy methodology for Ovarian Cancer
Dataset-Fisher Score and ARD











External Cross Validation Test Accuracy
72.2
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Table B.8: Results of the biased test accuracy methodology for Ovarian Cancer
Dataset-Information Gain and ARD











External Cross Validation Test Accuracy
72.2
Let us take a closer look at R1, we have applied filter method and ARD on
all the folders (k1 to k10, or K−1) before we create the training and testing data
based on the ARD ranking for internal cross validation. This is not a correct way
as we have allowed the testing data in the internal cross validation to be learnt by
the feature selection methods. Since the data is learnt beforehand, the results of
the internal cross validation is better than external cross validation. During R1,
K1 is not used for any training in the internal cross validation.
Generally, this problem is not significant if there are a lot of examples. How-
ever, in view of the small number of examples to be learnt in the DNA Microarray
datasets, the effect of selection bias will be significant. We will end up choosing
the wrong number of optimal features due to this bias.
The biased test accuracy methodology is discussed here and not used for further
comparison. Yet, it verified that the concern of Ambroise and McLachlan (2002)




Analysis on ARD values
In Gaussian Processes, ARD values (Θ) are the products of MCMC samplings on
the equilibrium distribution. From the discussion in section 3.2, the ARD values
contain precious information on the features of the original input data. Besides
knowing that it is a measure of the importance of a feature, we try to understand
whether there is other information that we can cultivate from the ARD values.
For this purpose, we have used the Principle Components Analysis.
The dataset we used is Robotic Arm dataset. The dataset consists of two
features as its inputs and one output. There are 200 number of training examples
and 200 testing examples. The data can be found in:
http : //www.inference.phy.cam.ac.uk/mackay/BayesFAQ.html]Data
We used a regression problem as the simulation would be much faster than
that of a classification problem. A huge data can be obtained instantly for further
study. This dataset consists of 2 features (relevant features) originally. We have
added two redundant features and two irrelevant features. Different noise are
added in for the redundant features.
We will only discuss mainly two datasets that we generated based on Robotic
Arm dataset. One is without noise when we generate the redundant features,
which means the two features are the exact duplicates of the relevant features.
81

















 Redundant 1Relevant 1 
Redundant 2 
Relevant 2 
Irrelevant 1 Irrelevant 2 
Figure C.1: ARD values for Robotic Arm dataset without noise. Only iterations
after equilibrium distribution reached are shown here. Take note that the vertical
axis is the ARD values while the horizontal axis is the number of iterations.
Another one is with gaussian noise of 0.04 added when we create the redundant
features. The ARD of the two datasets are shown in Figure C.1 and Figure C.2
respectively.
The figures show that equilibrium distribution is established.
Based on the simulation, we apply the PCA on the ARD values. Table C.1
and Table C.2 summarize the output.
Table C.1: Results of PCA based on Robotic Arm without noise
Eigenvalues Percentage Eigenvectors
0.18493 88.2763 −0.70957 0.00278 0.70442 −0.01016 0.01336 0.00276
0.02127 10.1526 −0.01675 0.70169 −0.03068 −0.71046 0.04010 0.00687
0.00260 1.2418 0.70417 0.03911 0.70880 −0.00787 0.01224 0.00277
0.00064 0.3099 0.01941 −0.71139 0.01151 −0.70139 0.03782 0.00495
0.00003 0.0140 −0.00046 0.00215 0.01276 −0.03777 −0.55499 −0.83090
0.00001 0.0053 −0.00065 0.00067 0.01231 −0.04131 −0.82983 0.55634
First columns of the tables are the eigenvalues of the new features. In this
case, it basically describes the spreading of the data in the new feature space.
The higher the value of the eigenvalue, the wider spread of the data is. Since the
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Figure C.2: ARD values for Robotic Arm dataset with noise. Only iterations after
equilibrium distribution reached are shown here. Take note that the vertical axis
is the ARD values while the horizontal axis is the number of iterations.
Table C.2: Results of PCA based on Robotic Arm with noise
Eigenvalues Percentage Eigenvectors
0.00462 71.8279 −0.99938 −0.03071 0.00010 −0.01538 0.00738 0.00180
0.00090 14.0594 0.02999 −0.98451 −0.16964 0.02613 0.01956 0.00240
0.00054 8.4008 0.01044 −0.16776 0.93415 −0.30982 0.05457 0.01210
0.00033 5.1356 −0.01302 −0.02570 0.30394 0.94733 0.09485 0.01914
0.00002 0.3826 −0.00557 −0.02086 0.05520 0.05157 −0.52767 −0.84581
0.00001 0.1937 −0.00536 −0.02383 0.05624 0.05478 −0.84211 0.53300
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spreading is huge, there are more information in this particular space. Meanwhile,
the lower value the eigenvalue of the new space, the smaller the spread. It may
mean that the data are all cluster near one point.
The second column is the percentage of the particular eigenvalue based on the
sum of eigenvalues. Eigenvector is how the feature space is being transpose to the
new feature space.
From the table, we can observe that when there are redundant features, the
PCA may fail to identify them. This is mainly due to the values of ARD. The ARD
values may (with noise) or may not (without noise) totally abandon redundant
features.
However, we can observe that irrelevant features can be detected in ARD
values. From both tables, eigenvalues of the 5th and 6th new features are very
small. And the two new features are only made up by the two irrelevant features.
In short, the two irrelevant features will form a two dimension space which are
orthogonal and the values of the two dimensions clustered at a relatively small
value. Visually, we can treat it as a thin plate in hyper-plane. It is thin as the
variance is small in value.
What we have learnt from here may not be useful in this project. Further
study may be required. Also, other unsupervised methods may be used as well for
exploring the further understanding of ARD values.
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